Aminocaproic Acid
Mechanism :
Aminocaproic acid is a monoamino carboxylic acid which acts as an effective inhibitor of fibrinolysis. The beneficial fibrinolysis-inhibitory effects of aminocaproic acid appear to be principally via inhibition of plasminogen activator substances and to a lesser degree, through antiplasmin activity.
Indication :
Contraindications :
Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid.
Dosing :
Oral: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24 g/day.
Adverse Effect :
Nausea, cramps, diarrhea, dizziness, tinnitus, malaise, conjunctival suffusion, nasal stuffiness, headache, myopathy and skin rash.
Interaction :
Prolongation of the template bleeding time has been reported during continuous intravenous infusion at dosages exceeding 24 g/day. Higher plasma concentrations may occur in patients with severe renal failure.
Hepatic Dose :
No dosage adjustments are recommended.